Ignite Creation Date:
2024-07-17 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06497049
Status:
COMPLETED
Last Update Posted:
2024-07-11
First Post:
2024-07-04
Brief Title:
Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221 GEROPHARM LLC Russia and Ozempic
Sponsor:
Geropharm
Organization:
Geropharm
Study Overview
Official Title:
An Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221 Solution for Subcutaneous Administration 134 mgml GEROPHARM and Ozempic Solution for Subcutaneous Administration 134 mgml in Healthy Volunteers
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Study of comparative pharmacokinetics and biosimilarity of drugs containing semaglutide - GP40221 and Ozempic in healthy volunteers
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None